Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat

被引:9
作者
Cavaletti, G
Petruccioli, MG
Marmiroli, P
Rigolio, R
Galbiati, S
Zoia, C
Ferrarese, C
Tagliabue, E
Dolci, C
Bayssas, M
Etienne, GG
Tredici, G
机构
[1] Univ Milan, Dipartimento Neurosci & Tecnol Biomed, Monza, Italy
[2] Univ Milano Statale, Dipartimento Anat Umana, Milan, Italy
[3] Debiopharm SA, Lausanne, Switzerland
关键词
nerve growth factor; neurotoxicity; oxaliplatin; rat;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: Oxaliplatin neurotaxicity represents a clinically-relevant problem and its etio-pathogenesis is still unknown. We explored the possible role of some neuronal growth factors ("neurotrophins") during the course of oxaliplatin sensory neuronopathy. Materials and Methods: In our rat model two different doses of oxaliplatin were used (2 and 3 mg/kg iv twice weekly for 9 times). The neurotoxicity of the treatment was assessed with neurophysiological and pathological methods and serum neurotrophin levels were measured by ELISA. Results: Both oxaliplatin-treated groups showed the neurophysiological and neuropathological changes which mimic the chronic effects of oxaliplatin administration in humans, e.g. reversible sensory impairment due to dorsal root ganglia neuron damage. These changes were associated with a significant and dose-dependent reduction only in the circulating level of nerve growth factor (NGF), which returned to normal values after neurophysiological and pathological recovery. Conclusion: This specific association between neurological impairment and NGF modulation indicates that NGF impairment has a role in the neurotaxicity of oxaliplatin.
引用
收藏
页码:4199 / 4204
页数:6
相关论文
共 43 条
[1]
Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by Cisplatin: behavioral, structural and biochemical analysis [J].
Aloe, L ;
Manni, L ;
Properzi, F ;
De Santis, S ;
Fiore, M .
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL, 2000, 86 (1-2) :84-93
[2]
Neurotrophic factor therapy - Prospects and problems [J].
Apfel, SC .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (04) :351-355
[3]
NERVE GROWTH-FACTOR PREVENTS EXPERIMENTAL CISPLATIN NEUROPATHY [J].
APFEL, SC ;
AREZZO, JC ;
LIPSON, L ;
KESSLER, JA .
ANNALS OF NEUROLOGY, 1992, 31 (01) :76-80
[4]
Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy [J].
Apfel, SC ;
Kessler, JA ;
Adornato, BT ;
Litchy, WJ ;
Sanders, C ;
Rask, CA .
NEUROLOGY, 1998, 51 (03) :695-702
[5]
Bergman E, 1999, J COMP NEUROL, V410, P368, DOI 10.1002/(SICI)1096-9861(19990802)410:3<368::AID-CNE2>3.0.CO
[6]
2-I
[7]
Carboplatin toxic effects on the peripheral nervous system of the rat [J].
Cavaletti, G ;
Fabbrica, D ;
Minoia, C ;
Frattola, L ;
Tredici, G .
ANNALS OF ONCOLOGY, 1998, 9 (04) :443-447
[8]
Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor [J].
Cavaletti, G ;
Pezzoni, G ;
Pisano, C ;
Oggioni, N ;
Sala, F ;
Zoia, C ;
Ferrarese, C ;
Marmiroli, P ;
Tredici, G .
NEUROSCIENCE LETTERS, 2002, 322 (02) :103-106
[9]
CAVALETTI G, 1992, ACTA NEUROPATHOL, V84, P364
[10]
PROTECTIVE EFFECTS OF GLUTATHIONE ON CISPLATIN NEUROTOXICITY IN RATS [J].
CAVALETTI, G ;
MINOIA, C ;
SCHIEPPATI, M ;
TREDICI, G .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (04) :771-776